跳至主要内容
临床试验/NCT01777438
NCT01777438已完成不适用

Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy

Universitaire Ziekenhuizen KU Leuven2 个研究点 分布在 1 个国家目标入组 434 人开始时间: 2012年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
434
试验地点
2
主要终点
Degree of Symptom Control 3 Years After IT or 3 Years After Medical Treatment With VAS of Total Nasal Symptom < 5/10 Defined as a Controlled Situation.

研究概览

简要总结

Allergic rhinitis (AR) is defined as inflammation of the nasal mucosa after exposition to an allergen in sensitized patients. AR causes not only nasal symptoms such as sneezing, itchy nose, rhinorrhea and nasal obstruction, but also has a significant impact on quality of life. Symptom control and overall satisfaction in patients undergoing subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) on the long term has not yet been investigated so far.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
19 Years 至 59 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Patients with at least 2 AR symptoms and a positive skin prick test for the 20 most prevalent inhalant allergens (house dust mites, grass pollen, tree pollen, animal dander, Alternaria, Penicillium and Cladosporium) in Belgium.
  • •Moderate/severe and/or persistent AR according to ARIA guidelines
  • •Age > 18 and < 60 years.
  • •Written informed consent
  • •Dutch, French or English speaking patients

排除标准

  • •Exclusion criteria
  • •Age < 18 and > 60 years
  • •Patients with mild AR
  • •Patients not being able to give an informed consent
  • •Patients being enrolled in other clinical trials
  • •No knowledge of Dutch, French or English

结局指标

主要结局

Degree of Symptom Control 3 Years After IT or 3 Years After Medical Treatment With VAS of Total Nasal Symptom < 5/10 Defined as a Controlled Situation.

时间窗: 3 years after diagnosis

Visual analogue scale (VAS) scores for TNS experienced during the last 4 weeks. Visual analog scales (VAS) have been used to rate the presence of symptoms or impairment of the daily activities. Patients had to answer each question by indicating a position with a vertical line between two endpoints, 0 cm for not bothersome versus 10 cm for extremely bothersome. In this way each question is scored between 0 and 10 points.

Current Medication Use Three Years After Diagnosis of AR

时间窗: 3 years after starting SCIT

Percentage patients in both groups that still use medication for their allergic rhinitis symptoms, 3 years after starting their therapy (non IT-group vs IT-group)

次要结局

  • Percentage of Patients Having Controlled Allergic Rhinosinusitis (AR) Symptoms 3 Years After Starting Treatment(3 years after starting SCIT)
  • Percentage of Patients That Met ARIA Criteria for Mild AR Symtoms at a Mean Interval of 3 Years After Diagnosis(3 years after diagnosis)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验